首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備

市場調查報告書

商品編碼

1410183

全球注射器市場：預測（2023-2028）

Global Syringe Market - Forecasts from 2023 to 2028

出版日期: 2023年12月12日 | 出版商:

Knowledge Sourcing Intelligence | 英文 112 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計2028年全球注射器市場規模將達99.08億美元，2023年至2028年複合年成長率為3.50%。

老年人口的增加是預測期內推動注射器產業成長的關鍵因素之一。老年人口的增加對注射器需求的增加產生了直接的正面影響，因為許多人隨著年齡的成長而生病。根據世界銀行資料，到2050年，65歲以上人口將達12.5億，比2020年增加約7570億。

慢性病增加

全球慢性病盛行率上升也是預期導致預測期內注射器需求增加的主要因素。例如，預計2021年全球糖尿病患者人數將達5.37億，2030年將達6.43億，2045年將達7.83億。此外，預計到 2021 年將有 5.41 億人出現糖耐量受損。此外，世界各地實施的免疫計劃數量不斷增加，人們對接種疫苗來應對各種疾病的認知不斷提高，也有助於注射器市場在預測期內的成長。

非傳染性疾病死亡率

由於現代生活方式缺乏其他活動，許多人患有各種慢性疾病，如類風濕性關節炎、糖尿病等。根據世界衛生組織（WHO）統計，每年發生的1,790萬例非傳染性疾病中，大部分是由心血管疾病引起的，其中包括惡性（930萬例）、慢性呼吸道疾病（410萬例）和糖尿病（糖尿病腎病變） ). 其次是 200 萬人（包括疾病死亡）。預計這將對注射器市場的成長產生積極影響，並有望補充注射器使用量的增加。

美國的慢性病

根據疾病管制與預防中心的數據，美國近十分之六的成年人患有慢性病，十分之四的人患有兩種或兩種以上慢性病。此外，根據國際糖尿病聯盟的數據，糖尿病患者人數預計將從 2021 年的 5.37 億增加到 2030 年的 6.34 億。因此，越來越多的人需要定期注射胰島素。全球糖尿病患者人數的上升趨勢以及領先公司不斷推出的市場產品預計將在未來幾年持續下去，並預計在評估期間推動注射器的需求。

美國注射器市場預計將穩定成長。

美國注射器的成長是由於該國糖尿病和癌症等慢性疾病的盛行率不斷上升。在美國，糖尿病患者正以顯著的速度增加。根據美國疾病管制與預防中心的數據，2022 年，有 3,730 萬人（即美國美國的 11.3%）患有糖尿病，其中 2,870 萬人被診斷出患有糖尿病，850 萬人患有未確診的糖尿病。在美國，18 歲以上的人中有 9,600 萬人患有前期糖尿病。因此，此類疾病在美國的盛行率正在增加，這正在推動注射器市場的成長。

美國移植數量

根據器官共享聯合網路的數據，美國共有 42,887 例移植手術，較 2021 年增加了 3.7%。 2022年腎臟移植數量為25,498例，與前一年同期比較增加3.4%，其次為肝臟移植9,528例，心臟移植4,111例，肺移植2,692例。隨著美國疾病數量和治療方法的不斷增加，注射器市場有望進一步擴大。

市場主要發展

2022 年10 月，泰爾茂(Terumo) 的一個部門、主要容器、注射劑和輸液治療設備製造商泰爾茂製藥解決方案(TPS) 宣布推出一款容量更大的即用型聚合物注射器，可應對具有挑戰性的生物製藥應用。 PLAJEX 2.25 mL 錐形針專為生物技術領域開發，適用於高黏度生物技術藥物等困難的藥物應用。 2022年1月，總部位於美國西哥倫比亞的Nephron Pharmaceuticals Corporation推出了環烯烴共聚物（COC）注射器。這款 COC 注射器具有玻璃般的外觀，但不易破碎且重量輕。

The rise in the geriatric population is one of the major factors anticipated to propel the growth of the global syringe industry during the forecast period. As many people acquire diseases as they age, the increasing elderly population has a direct positive impact on the rising demand for syringes. According to data from the World Bank, there will be 1.25 billion individuals aged 65 and older by 2050, an increase of about 757 million from 2020.

Rising prevalence of chronic diseases

The rising prevalence of chronic diseases worldwide is another major factor that is expected to lead to the rising demand for syringes during the forecasted period. For instance, the number of persons with diabetes worldwide was predicted to reach 537 million in 2021, 643 million in 2030, and 783 million in 2045. Additionally, it is anticipated that 541 million individuals will have reduced glucose tolerance by 2021. Moreover, an increasing number of immunization programs being conducted around the world, coupled with increased awareness among people for the need for immunization to tackle various diseases, is anticipated to bolster the growth of the global syringe market during the forecast period.

Death rate by non-communicable diseases

Owing to the lack of physical activities in the modern lifestyle, a number of people suffer from various kinds of chronic diseases like cardiovascular diseases, rheumatoid arthritis, and diabetes, among many others. According to the World Health Organization (WHO), the majority of NCDs, or 17.9 million fatalities each year, are caused by cardiovascular illnesses, followed by malignancies (9.3 million), chronic respiratory conditions (4.1 million), and diabetes (2.0 million, including deaths from renal disease brought on by diabetes). This is expected to have a positive impact on the global syringe market growth and is anticipated to supplement the rise in the use of syringes.

Chronic diseases in Americans

The Centers for Disease Control and Prevention states that nearly six in ten adults in the United States have a chronic disease while four in ten adults have two or more chronic diseases. Furthermore, according to the International Diabetes Federation, the number of people with diabetes is projected to grow from 537 million in 2021 to 634 million in 2030. This is leading to an increased number of people who need regular insulin injections. The increasing trend for diabetics around the world and the increased launch of market products by the major players is projected to continue in the coming years and is anticipated to boost the demand for syringes during the assessment period.

It is projected that the syringe market in the United States will grow steadily.

The growth of syringes in the United States can be attributed to the rising prevalence of chronic diseases like diabetes and cancer in the country. Diabetes is increasing at a significant rate in the United States. According to the Centers for Disease Control and Prevention in 2022, 37.3 million people or 11.3% of the US population were suffering from diabetes, out of which 28.7 million people had been diagnosed with diabetes and 8.5 million people suffered from undiagnosed diabetes. 96 million people aged 18 years or older have become prediabetes in the United States. Hence, the prevalence of such diseases is increasing in the States which in turn is propelling the syringe market growth.

Number of transplants in the United States

According to the United Network for Organ Sharing, the total number of transplants in the United States were 42,887 a 3.7% increase over 2021, and the highest transplants happened for kidney. The kidney transplant statistics for 2022 were 25,498 in the States which is an increase of 3.4% over the previous year, followed by liver, heart, and lung transplants with 9,528, 4,111, and 2,692 transplants respectively. Therefore, with an increase in diseases and an increase in ways to treat them growing in the country, this will help in further expanding the global syringe market in the United States.

Market Key Developments

In October 2022, a ready-to-fill polymer syringe with a greater volume for difficult biotech medications was introduced by Terumo Pharmaceutical Solutions (TPS), a part of Terumo Corporation and maker of primary container, injection, and infusion treatment devices. Specifically created for the biotech sector, the PLAJEX 2.25 mL with Tapered Needle is appropriate for difficult drug applications, such as high-viscosity biotech drugs.
In January 2022, Nephron Pharmaceuticals Corporation, a company based in West Columbia, United States, launched the Cyclic Olefin Copolymer syringe (COC). These COC syringes have a glass-like appearance, but they are break-resistant and lightweight.

Segmentation:

By Type

Insulin Syringe
Conventional Syringe
Eccentric Tip Syringe
Catheter Tip Syringe
Luer Lock Syringe

By Material

Glass
Plastic
Stainless Steel

By Syringe Size

Smaller Volume Syringe
Larger Volume Syringe

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
India
Japan
South Korea
Taiwan
Thailand
Indonesia
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. GLOBAL SYRINGE MARKET BY TYPE

5.1. Introduction
5.2. Insulin Syringe
5.3. Conventional Syringe
- 5.3.1. Eccentric Tip Syringe
- 5.3.2. Catheter Tip Syringe
- 5.3.3. Luer Lock Syringe

6. GLOBAL SYRINGE MARKET BY MATERIAL

6.1. Introduction
6.2. Glass
6.3. Plastic
6.4. Stainless Steel

7. GLOBAL SYRINGE MARKET BY SYRINGE SIZE

7.1. Introduction
7.2. Smaller Volume Syringe
7.3. Larger Volume Syringe

8. GLOBAL SYRINGE MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. USA
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. Germany
- 8.4.2. France
- 8.4.3. United Kingdom
- 8.4.4. Others
8.5. Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Others
8.6. Asia Pacifi
- 8.6.1. China
- 8.6.2. India
- 8.6.3. Japan
- 8.6.4. South Korea
- 8.6.5. Taiwan
- 8.6.6. Thailand
- 8.6.7. Indonesia
- 8.6.8. Others